Skip to results

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme (1 selected)

Guidance programme

Showing 1 to 25 of 769

Published guidance, NICE advice and quality standards
TitleReference numberPublishedLast updated
Lebrikizumab for treating moderate to severe atopic dermatitis in people 12 years and overTA986
Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (terminated appraisal)TA987
Selective internal radiation therapy with QuiremSpheres for treating unresectable advanced hepatocellular carcinomaTA985
Selective internal radiation therapies for treating hepatocellular carcinomaTA688
Tafamidis for treating transthyretin amyloidosis with cardiomyopathyTA984
Baricitinib for treating juvenile idiopathic arthritis in people 2 years and over (terminated appraisal)TA982
Voxelotor for treating haemolytic anaemia caused by sickle cell diseaseTA981
Pembrolizumab with trastuzumab and chemotherapy for untreated locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinomaTA983
Ivosidenib with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutationTA979
Nivolumab for adjuvant treatment of completely resected melanoma at high risk of recurrence in people 12 years and over (terminated appraisal)TA980
Trastuzumab deruxtecan for treating HER2-mutated advanced non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal)TA976
Dabrafenib with trametinib for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and overTA977
Zanubrutinib with obinutuzumab for treating relapsed or refractory B-cell follicular lymphoma after 2 or more treatments (terminated appraisal)TA978
Sirolimus for treating facial angiofibroma caused by tuberous sclerosis complex in people 6 years and over (terminated appraisal)TA972
Natalizumab for the treatment of adults with highly active relapsing–remitting multiple sclerosisTA127
Alemtuzumab for treating highly active relapsing–remitting multiple sclerosisTA312
Cladribine for treating relapsing–remitting multiple sclerosisTA616
Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusionTA283
Ranibizumab and pegaptanib for the treatment of age-related macular degenerationTA155
Ranibizumab for treating choroidal neovascularisation associated with pathological myopiaTA298
Atogepant for preventing migraineTA973
Selinexor with bortezomib and dexamethasone for previously treated multiple myelomaTA974
Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and underTA975
Selinexor with dexamethasone for treating relapsed or refractory multiple myeloma after 4 or more treatmentsTA970
Remdesivir and tixagevimab plus cilgavimab for treating COVID-19TA971

Results per page

  1. 10
  2. 25
  3. 50
  4. All